Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
- 17 July 2008
- journal article
- case report
- Published by Springer Nature in International Journal of Hematology
- Vol. 88 (2) , 219-222
Abstract
We present here a case of severe congestive cardiac failure, in a 47-year-old patient with myeloma who had no prior cardiac history, after receiving bortezomib. Bortezomib is a boron-containing molecule, which reversibly inhibits the proteasome, an intracellular organelle, which is central to the breakdown of ubiquitinated proteins and consequently crucial for normal cellular homeostasis. Phase II clinical trials demonstrate that it is effective for the treatment of relapsed refractory myeloma. Acute development of congestive cardiac failure associated with bortezomib therapy occurs very rarely or may be underestimated. Inhibition of proteasome activity may impair cardiac function due to accumulation of unfolded, damaged and undegraded proteins in myocytes. Patients with or without cardiac disease or previously received anthracycline-containing regimes should be closely monitored when being subjected to treatment with bortezomib.Keywords
This publication has 16 references indexed in Scilit:
- Unexpected cardiotoxicity in haematological bortezomib treated patientsBritish Journal of Haematology, 2007
- New Drugs for MyelomaThe Oncologist, 2007
- Weekly Bortezomib/Methylprednisolone is Effective and Well Tolerated in Relapsed Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2006
- The ubiquitin-proteasome system in cardiac physiology and pathologyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Proteasome inhibition as novel treatment strategy in leukaemiaBritish Journal of Haematology, 2006
- The ubiquitin–proteasome system: Focus on the heartCardiovascular Research, 2006
- Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-κBJournal of Biological Chemistry, 2004
- The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extendedCardiovascular Research, 2004
- Protein degradation and protection against misfolded or damaged proteinsNature, 2003
- Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other CancersCancer Control, 2003